Abstract
Aim: While China has become a significant contributor and prolific publisher in regenerative medicine, its role in the field is not well understood. We analyze how capacity in regenerative medicine was built in China to identify some of its main strengths and challenges. Materials & methods: This case study of regenerative medicine in China is primarily based on interviews with experts in China, including researchers, policy makers, clinicians, representatives of firms and regulators. Results: Our analysis shows that diverse groups are active in this field in China. Leading research groups are contributing extensively to international peer-reviewed journals. Strong governmental support and recruitment of highly trained Chinese scientists from abroad has made it possible for China to rapidly build up capacity in regenerative medicine. However, some hospitals in China are offering stem cell therapies with limited scientific evidence supporting their efficacy/safety, and international skepticism of medical research in China presents a challenge to the development of the field. Conclusion: China has been able to catapult itself into the forefront of regenerative medicine but needs to address current regulatory challenges in order to secure its position in this emerging field.
Bibliography
- 1 Zweig D: Competing for talent: China’s strategies to reverse the brain drain. Int. Labour Rev.145,65–89 (2006).
- 2 Tong DZ, Wu SQ, Ye YF, Yang SY, Du M, Lu DY: Nuclear transfer in fishes. Chinese Sci. Bull.7,60–61 (1963).
- 3 Tong DZ, Ye YH, Lu DY, Tong SM, Du M: Transplantation of nuclei between two subfamilies of teleosts. Acta Zool. Sin.19,201–207 (1973).
- 4 Zhou Q, Renard J, Le Friec G: Generation of fertile cloned rats by regulating oocyte activation. Science302,1179 (2003).
- 5 Chen Y, He ZX, Liu AL et al.: Embryonic stem cells generated by nuclear transfer of human somatic nuclei into rabbit oocytes. Cell Res.13,251–263 (2003).
- 6 Abbott A, Dennis C, Ledford H, Smith K: The lure of stem-cell lines. Nature442,336–337 (2006).
- 7 Guhr A, Kurtz A, Friedgen K, Loser P: Current state of human embryonic stem cell research: an overview of cell lines and their use in experimental work. Stem Cells24,2187–2191 (2006).
- 8 Liao LM, Zhao RC: An overview of stem cell-based clinical trials in China. Stem Cells Dev.17,613–618 (2008).
- 9 Cheng L, Xiao L, Zeng F, Zhang YA: Stem cells shine in Shanghai. Cell Stem Cell2,34–37 (2008).
- 10 Lander B, Thorsteinsdóttir H, Singer PA, Abdallah AS: Harnessing stem cells for health needs in India. Cell Stem Cell3,11–15 (2008).
- 11 Guest J, Herrera LP, Qian T: Rapid recovery of segmental neurological function in a tetraplegic patient following transplantation of fetal olfactory bulb-derived cells. Spinal Cord44,135–142 (2006).
- 12 Dobkin BH, Curt A, Guest J: Cellular transplants in China: observational study from the largest human experiment in chronic spinal cord injury. Neurorehabil. Neural Repair20,5–14 (2006).
- 13 Radtke C, Sasaki M, Lankford KL, Vogt PM, Kocsis JD: Potential of olfactory ensheathing cells for cell-based therapy in spinal cord injury. J. Rehabil. Res. Dev.45,141–152 (2008).
- 14 Liao LM, Li LS, Zhao RC: Stem cell research in China. Philos. Trans. R. Soc. Lond., B, Biol. Sci.362,1107–1112 (2007).
- 15 Doring O: China’s struggle for practical regulations in medical ethics. Nat. Rev. Gen.4,233–239 (2003).
- 16 Chinese National Human Genome Center at Shanghai, Ethics Committee: Ethical guidelines for human embryonic stem cell research (a recommended manuscript). Kennedy Inst. Ethics J.14,47–54 (2004).
- 17 Ministry of Science and Technology; Ministry of Health: Ethical guiding principles for human embryonic stem cell research. People’s Republic of China (2003).
- 18 Hao X: Monkey research in China: developing a natural resource. Cell129,1033–1036 (2007).
- 19 Cheng L, Qiu RZ, Deng H, Zhang YA, Jin Y, Li L: Ethics: China already has clear stem-cell guidelines. Nature440,992 (2006).
- 20 Cyranoski D: Stem-cell therapy faces more scrutiny in China. Nature459,146–147 (2009).
- 21 Anonymous ISSCR Guidelines for the Clinical Translation of Stem Cells: Current Protocols in Stem Cell Biology. Appendix 1, 1B (2009).
- 22 Salter B, Cooper M, Dickins A: China and the global stem cell bioeconomy: an emerging political strategy? Regen. Med.1,671–683.
- 23 Frew S, Sammut SM, Shore AF et al.: Chinese health biotech and the billion-patient market. Nature Biotechnol.26,37–53 (2008).
- 24 Mandavilli A: Hui Zhen Sheng. Nat. Med.12,265–266 (2006).
- 101 Ministry of Science and Technology: China Science and Technology Statistics Data Book. People’s Republic of China (2007). www.most.gov.cn/eng/statistics/2007/index.htm
- 102 DTI Global Watch: Stem Cell Mission to China, Singapore and South Korea.DTI Global Watch Mission Report (2004). http://www.oti.globalwatchonline.com/online_pdfs/36206MR.pdf
- 103 ChinaSCINet. www.chinascinet.org/
- 104 Beike Biotech. www.beikebiotech.com
- 105 Tiantan Puhua Stem Cell Treatment Center. www.stemcellspuhua.com
- 106 Neuro-Regeneration, Repair and Functional Recovery. www.nrrfr.com/
- 107 People’s Republic of China: profile of the 863 program: state high-tech development plan. www.863.org.cn/english/index.html
- 108 People’s Republic of China: profile of the 973 program: National Basic Research program of China. www.973.gov.cn/English/Index.aspx
- 109 UK Stem Cell Initiative [UKSCI]: Global positions on stem cell research. www.advisorybodies.doh.gov.uk/uksci/global/china.htm
- 110 International Stem Cell Forum: about ISCF members. Chinese Academy of Sciences. www.stemcellforum.org/about_the_iscf/members/chinese_academy_of_sciences.cfm
- 111 Wang Q: What kinds of overseas talents does China need? (2007). www.china.org.cn/english/education/196881.htm
